EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Fibroblast Growth Factor 21 Analogues Improve Fibrosis in Metabolic Dysfunction–Associated Steatohepatitis: An Updated Systematic Review and Meta‐Analysis

Muhammad Naqash, Abdullah Tariq, Shazma Shayan, Sadaf Manzoor Sargani, Muhammad Asad Raza, Nasar Nasrullah Khan, Aiman Balouch, Rana Muhammad Usama, Khabab Abbasher Hussien Mohamed Ahmed iD

International Journal of Hepatology · 2026-01 · 2026 (1)

DOI: 10.1155/ijh/7391450 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Hepatology, online erschienen am 03.06.2026. Verfasst von Muhammad Naqash und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hull University Teaching Hospitals NHS Trust, Hull, UK. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction–associated steatohepatitis (MASH) (formerly nonalcoholic steatohepatitis, MASH) is a growing cause of liver morbidity worldwide. Although therapeutic options for MASH fibrosis have expanded, including the approval of resmetirom for noncirrhotic MASH with F2–F3 fibrosis, additional therapies with antifibrotic efficacy remain needed. Fibroblast growth Factor 21 (FGF21) is a liver‐derived hormone that regulates lipid metabolism, insulin sensitivity, and energy balance, and long‐acting FGF21 analogues have shown promise in Phase 2 trials. We performed a systematic review and meta‐analysis to quantify the efficacy and safety of FGF21 analogues in improving liver fibrosis in MASH.

Methods

We searched PubMed, Scopus, and the Cochrane Library (through February 2026) for randomized controlled trials (RCTs) comparing an FGF21 analogue versus placebo in adults with biopsy‐confirmed MASH. Primary outcomes were ≥ 1‐stage histological fibrosis improvement without MASH worsening. Secondary outcomes included changes in hepatic fat, liver enzymes, and key metabolic parameters. Data were pooled using random‐effects models, calculating pooled risk ratios (RRs) or standardized mean differences (SMDs) with 95% confidence intervals (CI).

Results

We identified 10 RCTs (total: 1113 patients with F1–F4 fibrosis) meeting inclusion criteria. FGF21 analogue treatment significantly increased the likelihood of achieving ≥ 1‐stage fibrosis improvement (RR: 2.25, CI: 1.25–4.03) compared with placebo. FGF21 analogues also produced larger reductions in hepatic fat content, liver stiffness, and fibrosis biomarkers than placebo. The incidence of serious adverse events was similar between groups. The most reported treatment‐related side effects were gastrointestinal, especially nausea and diarrhea, and local injection reactions; these were generally mild and did not significantly limit therapy.

Conclusions

FGF21 analogue therapy is associated with significantly greater histological fibrosis improvement in patients with MASH and appears to be well tolerated. These findings suggest that FGF21 analogues may become a valuable pharmacotherapy for MASH, but confirmatory larger trials and long‐term data are needed.

Schlagwörter

Stichwörter der Autor:innen

fibroblast growth Factor 21 (FGF21)liver fibrosisliver-derived hormonemetabolic dysfunction–associated steatohepatitis (MASH)nonalcoholic fatty liver disease (NAFLD)

Autor:innen und Institutionen

  • Hull University Teaching Hospitals NHS Trust, Hull, UK.
  • Nottingham University Hospital NHS Trust, Nottingham, UK, nhs.uk.
  • Hull University Teaching Hospitals NHS Foundation Trust, Hull, UK.
  • Northern Lincolnshire and Goole NHS Foundation Trust, Scunthorpe, UK, nhs.uk.
  • Lahore General Hospital, Lahore, Pakistan.
  • Faculty of Medicine, University of Khartoum, Khartoum, Sudan, uofk.edu.

ORCID-Profile: Khabab Abbasher Hussien Mohamed Ahmed

Zitieren

APA

Naqash, M., Tariq, A., Shayan, S., Sargani, S. M., Raza, M. A., Khan, N. N., Balouch, A., Usama, R. M., & Ahmed, K. A. H. M. (2026). Fibroblast Growth Factor 21 Analogues Improve Fibrosis in Metabolic Dysfunction–Associated Steatohepatitis: An Updated Systematic Review and Meta‐Analysis. International Journal of Hepatology, 2026(1). https://doi.org/10.1155/ijh/7391450

Vancouver

Naqash M, Tariq A, Shayan S, Sargani SM, Raza MA, Khan NN, et al. Fibroblast Growth Factor 21 Analogues Improve Fibrosis in Metabolic Dysfunction–Associated Steatohepatitis: An Updated Systematic Review and Meta‐Analysis. International Journal of Hepatology. 2026;2026(1). doi:10.1155/ijh/7391450

BibTeX
@article{Naqash2026,
  author = {Naqash, Muhammad and Tariq, Abdullah and Shayan, Shazma and Sargani, Sadaf Manzoor and Raza, Muhammad Asad and Khan, Nasar Nasrullah and Balouch, Aiman and Usama, Rana Muhammad and Ahmed, Khabab Abbasher Hussien Mohamed},
  title = {Fibroblast Growth Factor 21 Analogues Improve Fibrosis in Metabolic Dysfunction–Associated Steatohepatitis: An Updated Systematic Review and Meta‐Analysis},
  journal = {International Journal of Hepatology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ijh/7391450}
}
Kostenlos starten →